Study: Edwards’ Sapien and Medtronic’s CoreValve outcomes are similar

A new study published in the Journal of the American College of Cardiology found that patients treated with Edwards Lifesciences‘s (NYSE:EW) and Medtronic‘s (NYSE:MDT) CoreValve showed similar results after 1 year. The 241-patient trial examined high-risk patients with symptomatic severe aortic stenosis 1 year after being treated with either Edwards’s Sapien balloon expanding or Medtronic’ self-expanding transcatheter heart valve. The rates of all-cause death and cardiovascular death were not statistically different between the groups, with a 3-5% difference between the 2 devices, according to the study. Stroke frequency and heart failure-related hospitalizations didn’t ping as statistically different, with a 4-6% maximum difference between the devices. Researches did report that more-than-mild paravalvular regurgitation was more common in the CoreValve group. The researchers concluded that despite a higher device success rate found initially in the Choice trial with the Edwards device, 1-year follow-ups showed similar outcomes between the 2 devices. Initial results from the study offered a mixed safety profile comparing the rival 1st-generation transcatheter aortic valve implantation systems. The study showed patients in the study who received Medtronic’s CoreValve implant were more likely to have aortic regurgitation (AR) following surgery, but AR was associated with a “significantly worse outcome” only in Sapien patients, accord...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Cardiac Implants Cardiovascular Clinical Trials Edwards Lifesciences medtronic Source Type: news